Log In
BCIQ
Print this Print this
 

ACU-193

  Manage Alerts
Collapse Summary General Information
Company Acumen Pharmaceuticals Inc.
DescriptionHumanized lgG2 mAb
Molecular Target Amyloid-beta derived diffusible ligands (ADDLS)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today